[1]戴 璐,宋欣丽,王 健.青藤碱联合甲氨蝶呤对类风湿性关节炎患者血清炎症因子的 影响及治疗安全性分析*[J].陕西医学杂志,2018,(12):1580-1583.
　Dai Lu,Song Xinli,Wang Jian.Effects of sinomenine combined with methotrexate on serum inflammatory factors in patients with rheumatoid arthritis and its safety[J].,2018,(12):1580-1583.
点击复制

青藤碱联合甲氨蝶呤对类风湿性关节炎患者血清炎症因子的 影响及治疗安全性分析*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2018年12期
页码:
1580-1583
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
Effects of sinomenine combined with methotrexate on serum inflammatory factors in patients with rheumatoid arthritis and its safety
文章编号:
DOI:10.3969/j.issn.1000-7377.2018.12.019
作者:
戴 璐; 宋欣丽; 王 健
西安市第五医院骨质疏松科（西安710082）
Author(s):
Dai Lu; Song Xinli; Wang Jian
Osteoporosis Department of Xi'an No.5 Hospital (Xi’an 710082)
关键词:
关节炎; 类风湿/药物疗法 青藤碱/治疗应用 甲氨蝶呤/治疗应用 炎症介导素类/血液
Keywords:
Key words Arthritis; rheumatoid/drug therapy Sinomenine/therapeutic use Methotrexate/therapeutic uses Inflammation mediators/blood
分类号:
R593.2
文献标志码:
A
摘要:
摘 要 目的：研究青藤碱联合甲氨蝶呤对类风湿性关节炎(RA)患者血清炎症因子的影响及治疗安全性。方法：选取确诊为RA患者120例，根据随机数字表法分为联合组和MTX组各60例。对照组在常规治疗的基础上使用MTX进行治疗，观察组在对照组的基础上使用SIN两组均治疗12周。观察患者血清炎症因子（包括IL-1、IL-4、IL-17、IL-13、IL-33、TNF-α、IFN-γ）、临床症状［肿胀关节数量、压痛关节数量、患者评分（PGA）、晨僵时间和RA患者病情评价表（DAS28）］和不良反应（胃肠道反应、肝肾功能损害、皮炎、头痛、白细胞减少、口腔溃疡和脱发）的变化。结果：与治疗前相比，联合组和MTX组的血清炎症因子水平显著较低（P＜0.05）；治疗后，MTX组的血清炎症因子水平显著高于联合组（P＜0.05）。联合组和MTX组的肿胀关节数量、压痛关节数量、PGA评分、晨僵时间和DAS28评分显著较低（P＜0.05）；治疗后，MTX组的肿胀关节数量、压痛关节数量、PGA评分、晨僵时间和DAS28评分显著高于联合组（P＜0.05）。联合组和MTX组均出现了副反应，其中，与联合组相比，MTX组的不良发生反应率显著较高（P＜0.05）。结论：MTX和SIN联合应用能够降低RA患者的血清炎症因子水平，改善临床症状，同时并能降低不良反应发生率，具有良好的治疗效果和安全性。
Abstract:
Abstract Objective: To study the effects of sinomenine combined with methotrexate on serum inflammatory factors in patients with rheumatoid arthritis and its safety. Methods: 120 patients with the latest diagnosis of RA were selected and divided into the combined group and the MTX group according to the random number table method, 60 cases each.The control group was treated with MTX on the basis of conventional treatment, and the observation group was treated with SIN for 12 weeks on the basis of the control group. Observe the patient's serum inflammatory factors (including IL-1, IL-4, IL-17, IL-13, IL-33, TNF-α, IFN-γ),clinical symptoms (number of swollen joints, number of tender joints, patient score (PGA), morning stiffness time, and RA patient condition evaluation form (DAS28)), and adverse reactions (gastrointestinal reactions, liver and kidney dysfunction, dermatitis, headache, leukopenia, oral ulcers and hair loss).Results: Serum inflammatory factor levels were significantly lower in the combination group and the MTX group than before treatment (P<0.05).After treatment, serum inflammatory factor levels in the MTX group were significantly higher than those in the combination group (P<0.05). The number of swollen joints, number of tender joints, PGA score, morning stiffness time and DAS28 scores in the combined group and the MTX group were significantly lower (P<0.05).After treatment, the number of swollen joints, number of tender joints, PGA score, morning stiffness time and DAS28 score in the MTX group were significantly higher than those in the combined group (P<0.05).Side effects were observed in both the combination group and the MTX group, and the adverse reaction rate was significantly higher in the MTX group than in the combination group (P<0.05). Conclusion: The combination of MTX and SIN can reduce the level of serum inflammatory〖LM〗 factors in patients with RA, improve clinical symptoms, and reduce the incidence of adverse reactions. It has good therapeutic effect and safety.

参考文献/References:


[1] 陆柳丹,韦 嵩. 中医治疗类风湿性关节炎研究进展[J]. 辽宁中医药大学学报,2013,15(08):86-88.
[2] 宋明霞. 类风湿性关节炎治疗现状[J]. 中医药临床杂志,2017,29(8):1200-1204.
[3] 黄 玲. 甲氨蝶呤治疗类风湿关节炎常见不良反应分析[J]. 中国药物经济学,2013，(1):83-84.
[4] 张梦颖. 青藤碱联合甲氨蝶呤治疗类风湿性关节炎的疗效及其作用机制的探究[D].南京中医药大学,2013.
[5] 李世梅, 王黎明, 陈继正,等. 鹿瓜多肽、丹参酮ⅡA联合DMARDs治疗类风湿性关节炎疗效观察[J]. 陕西医学杂志, 2015，44(6):744-746.
[6] 邢铁艳, 陈慕芝. 中医辨证分型治疗类风湿关节炎的临床疗效[J]. 陕西中医, 2016, 37(1):78-79.
[7] 汤荣华,黄建军. 类风湿性关节炎患者血清GM-CSF、IL-6、IL-17和TNF-α的水平测定及临床意义[J]. 检验医学,2013,28(3):173-177.
[8] Krishnamurthy A, Joshua V, Hensvold AH, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss[J]. Annals of the Rheumatic Diseases, 2016, 75(4):721-729.
[9] 安丽欣. 血清IL-18、IL-22、IL-23表达在类风湿性关节炎中的意义[J]. 国际检验医学杂志,2018,39(7):801-804.〖ZK)〗
[10] 周文旭, 方 堃, 谭湘淑,等. 甲氨蝶呤对类风湿性关节炎大鼠滑膜细胞凋亡基因调控的实验研究[J]. 陕西医学杂志, 2018，47(4):411-413，416.
[11] Robak T, Gladalska A, Stepien H, et al. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis[J]. Mediators of Inflammation, 2016, 7(5):347.
[12] 安香珍, 杨红霞, 邢燕军,等. 五联疗法对类风湿关节炎患者血清IL-37、IFN-γ、CD-62p、CD-41水平的影响[J]. 现代中西医结合杂志, 2016, 25(28):3095-3097.
[13] 周 彬,周迎莉,林为民,等. 青藤碱联合甲氨蝶呤对类风湿关节炎患者IL-1,IL-17和TNF-α表达的影响[J]. 现代中西医结合杂志,2014,23(19):2066-2068.
[14] 王梁谦,唐 杨,李修洋,等. 血清中炎性细胞因子在类风湿关节炎患者中的检测及临床意义[J]. 海南医学院学报,2016,22(8):762-764.
[15] 田军伟,陶鹏飞. 艾拉莫德联合甲氨蝶呤对类风湿性关节炎患者血清M-CSF、IL-6、IL-8及骨代谢的影响[J]. 海南医学,2017,28(3):391-394.
[16] 李 娟, 陈庆平, 刘佳钰,等. 艾拉莫德与甲氨蝶呤配伍治疗老年类风湿关节炎84例[J]. 陕西医学杂志, 2016, 45(1):120-121.
[17] 丁从珠. 青藤碱联合甲氨蝶呤抑制类风湿关节炎骨破坏的作用及机制研究[D].南京中医药大学,2012.
[18] 孙越华,朱 清,李俊旭. 青藤碱抗炎免疫与抗肿瘤作用研究新进展[J]. 中国药理学通报,2015,31(8):1040-1043.
[19] 周洁如,邓 筠,李 凝,等. 青藤碱联合甲氨蝶呤对RA患者外周血Treg及Th17细胞的影响及其临床意义[J]. 现代免疫学,2013,33(1):46-51.
[20] 陈庆平, 史雅峰, 沈斯瑶,等. 类风湿关节炎实验室诊断指标与DAS28评分相关性的研究[J]. 陕西医学杂志, 2012, 41(11):1469-1470.
[21] 顾 菲,孙 玥,陈思文,等. 青藤碱联合甲氨蝶呤治疗活动性类风湿关节炎临床研究[J]. 上海中医药杂志,2014,48(6):58-60.
[22] 钱 鑫,赵智明,张蓓蓓,等. 青藤碱对类风湿关节炎患者炎性细胞因子及免疫系统的影响. 中药材,2018，(5):1228-1230.

相似文献/References:

[1]李铭,高云,于赟,等.胎盘多肽、鹿瓜多肽联合抗风湿类药物治疗类风湿性关节炎临床观察[J].陕西医学杂志,2016,(10):1413.
[2]李丹,耿玲玲,冯媛,等.强克治疗幼年特发性关节炎48例对照观察[J].陕西医学杂志,2016,(09):1220.
　Li Dan,Geng Lingling,Feng Yuan,et al.[J].,2016,(12):1220.

备注/Memo

备注/Memo:
*陕西省自然科学基金资助项目(BK2010357)
更新日期/Last Update: 2019-01-21